ClinicalTrials.gov
ClinicalTrials.gov Menu

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01665768
Recruitment Status : Active, not recruiting
First Posted : August 15, 2012
Last Update Posted : July 13, 2017
Sponsor:
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : July 2020
  Estimated Study Completion Date : July 2020

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 November 9, 2018
December 7, 2018
2 December 12, 2018